Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis

Not Applicable

Active, not recruiting

• Conditions: Nocturnal Enuresis in Children; Desmopressin; Monosymptomatic Nocturnal Enuresis
• Interventions: Drug: Ginkgo Biloba oral tablet; Drug: Desmopressin Acetate 0.2 mg Tablets; Drug: Placebo

• Registration Number: NCT06771128
• Lead Sponsor: Menoufia University

Brief Summary

the efficacy of Ginkgo Biloba versus desmopressin in treatment of children with monosymptomatic nocturnal enuresis

Detailed Description

Bedwetting among children is a common disorder, affecting 30% at age 4, 10% at age 6, 3% at age 12, and 1% at age. Untreated, the spontaneous cure rate is about 15% a year. Treatment is dominated by two approaches, enuresis alarm and drugs.

Treatment with drugs has largely been focused on tricyclic antidepressants especially imipramine or, more recently, antidiuretic agents such as desmopressin. For imipramine the proportion of total remission is 10-50% during treatment and a long term cure in 5-40%. However, numerous reports of side effects, some lethal, have led to a decline in its use.

One of theory of nocturnal enuresis is deep sleep in children, this the main cornerstone in using Alarm as line of management.

On the other hand drugs used in re-habitation of sleep rhythm seems to be with great benefits in management as GINKGO BILOBA.

Ginkgo biloba leave extract is among the most widely sold herbal dietary supplements in the United States. Its purported biological effects include: scavenging free radical; lowering oxidative stress; reducing neural damages, reducing platelets aggregation; anti-inflammation; anti-tumor activities; anti-aging, and improve night sleep rhythm.

the aim of this study is to evaluate the effect of Ginkgo Biloba versus desmopressin in treatment of children with monosymptomatic nocturnal enuresis.

Study Timeline

• Study Start: 2024-11-01
• Study First Submitted: 2025-01-07
• Study First Submitted QC: 2025-01-07
• Study First Posted: 2025-01-13
• Primary Completion: 2025-07-01
• Status Verified: 2025-09
• Last Update Submitted: 2025-09-08
• Last Update Posted: 2025-09-15
• Study Completion: 2025-10-01

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

• all children with monosymptomatic nocturnal enuresis.

Exclusion Criteria

• children with day and night wetting.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Ginkgo Biloba group	Ginkgo Biloba oral tablet	Patients in this group receive Ginkgo Biloba oral tablet.
Desmopressin group	Desmopressin Acetate 0.2 mg Tablets	Patients in this group receive Desmopressin oral tablets.
Combination group	Ginkgo Biloba oral tablet	Patients in this group receive both Ginkgo Biloba and desmopressin oral tablets.
Combination group	Desmopressin Acetate 0.2 mg Tablets	Patients in this group receive both Ginkgo Biloba and desmopressin oral tablets.
Placebo group	Placebo	Patients in this group receive Placebo oral tablet.

Primary Outcome Measures

Name	Time	Method
Night wetting frequency	1, 3 months	Night wetting frequency is measured by the number of wet nights per week.

Trial Locations

Locations (1)

Menoufia Faculty of Medicine; 🇪🇬 Shebin El-Kom, Menoufia, Egypt

Menoufia Faculty of Medicine

🇪🇬Shebin El-Kom, Menoufia, Egypt

Mohamed Aziz

Contact

+201023321949

Mohammed_aziz2006@yahoo.com